Host genetics

Current Opinion in HIV and AIDS

Volumn 6, Issue 6, 2011, Pages 491-500

  Macías, Juan ^a   Vispo, Eugenia ^b   Pineda, Juan A ^a   Soriano, Vicente ^b  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

direct acting antiviral drugs; hepatitis C virus; IL28B; ITPA; pegylated interferon; ribavirin; rs12979860

Indexed keywords

INTERFERON; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN;

ANEMIA; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; GENETIC MARKER; GENOTYPE; HEPATITIS C; HOST SUSCEPTIBILITY; HUMAN; LIVER FIBROSIS; MEDICAL DECISION MAKING; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; INTERLEUKINS; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 80054884369     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834bca2d     Document Type: Review

References (54)

1. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa- 2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593.
2. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
3. vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIv-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13:429-437. (Pubitemid 352016736)
4. Mira JA, López-Cortés LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIv/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; 62:1365-1373.
5. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46:403-410. (Pubitemid 46185701)
6. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
7. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
8. Suppiah v, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
9. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345.
10. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138:2307-2314.
11. Rallón NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIv/hepatitis C virus-coinfected patients. AIDS 2010; 24:F23-F29.
12. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51:788'795
13. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
14. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011; 53:336-345.
15. Zhang L, Jilg N, Shao R-X, et al. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 2011; 55:1-10.
16. Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52:1888-1896.
17. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57:516-524.
18. Rallón N, Naggie S, Restrepo C, et al. IL28b plasma levels significantly increase after 4 weeks of therapy with P/R only in patients with the protective IL28B/rs12979860 genotype. 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, USA; abstract 948. Accessed at www. retroconference.org
19. Ruiz-Extremera A, Muñoz-Gámez JA, Salmerón-Ruiz MA, et al. Genetic variation in IL28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance inHCvinfected children. Hepatology 2011; 53:1830-1838.
20. Dring MM, Morrison MH, McSharry BP, et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A 2011; 108:5736-5741.
21. Bochud P-Y, Bibert S, Negro F, et al. IL28B polymorphisms predict reduction of HCv RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011. [Epub ahead of print]
22. Montes-Cano MA, García-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52:33-37.
23. Neukam K, Nattermann J, Rallón N, et al. Different distributions of hepatitis C virus genotypes among HIv-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. HIv Med 2011; 12:487-493.
24. Labarga P, Soriano v, Caruz A, et al. Association between IL28B gene polymorphisms and plasma HCv-RNA levels in HIv/HCv-co-infected patients. AIDS 2011; 25:761-766.
25. Abe H, Ochi H, Maekawa T, et al. Common variation of IL28 affects gamma- GTP levels and inflammation of the Liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53:439-443.
26. Bochud P-Y, Bibert S, Kutalik Z, et al. IL28B polymorphisms linked to poor response to treatment are associated with low necroinflammatory activity and slow fibrosis progression in HCv genotype non1-infected patients. J Hepatol 2011; 54 (Suppl. 1):S539.
27. Barreiro P, Pineda JA, Rallón N, et al. Influence of interleukin-28B singlenucleotide polymorphisms on progression to Liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis 2011; 203:1629-1636.
28. Fornasiere E, Cmet S, Bitetto D, et al. Interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Hepatol 2011; 54 (Suppl 1):S456-S457.
29. Aghemo A, Marabita F, De Nicola S, et al. Fibrosis progression in patients with chronic hepatitis c is not influenced by IL28B polymorphisms. J Hepatol 2011; 54 (Suppl 1):S519.
30. Rallón N, Soriano v, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIv/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25:1025-1033.
31. Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype vinfection. Hepatology 2011; 53:746-754.
32. Scherzer TM, Hofer H, Staettermayer AF, et al. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype vtreated with peginterferon alfa-2a and ribavirin. J Hepatol 2011; 54:866-871.
33. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or vpatients who do not achieve a rapid virologic response. Gastroenterology 2011; 139:821-827.
34. Sarrazin T, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and vinfected patients. J Hepatol 2011; 54:415-421.
35. Nattermann J, vogel M, Nischalke HD, et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIv-positive patients with acute and chronic hepatitis C. J Infect Dis 2011; 203:595-601.
36. Poordad F, Bronowicki J-P, Gordon SC, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. J Hepatol 2011; 54 (Suppl 1):S6.
37. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SvR rates across all IL28B genotypes in the ADvANCE trial. J Hepatol 2011; 54 (Suppl 1):S542-S543.
38. Pol S, Aerssens J, Zeuzem S, et al. Similar SvR rates in IL28B CC, CT or TT prior relapser partial- or null-responder patients treated with telaprevir/peginterferon/ ribavirin: retrospective analysis of the REALIZE study. Hepatol 2011; 54 (Suppl 1):S6-S7.
39. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52:421-429.
40. Aerssens J, Fanning G, Scholliers A, et al. Impact of IL28B genotype and pretreatment serum IP-10 in treatment-naive genotype-1 HCv patients treated with TMC435 in combination with peginterferon a-2a and ribavirin in PILLAR study. J Hepatol 2011; 54 (Suppl 1):S5-S6.
41. Medrano J, Neukam K, Rallón N, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIv. Clin Infect Dis 2010; 51:1209-1216.
42. Neukam K, Nattermann J, RallónN, et al. IL-28B GT influences chronification of hepatitis C in HIv/HCv GT 1/4 co-infected patients and efficiently predicts response to hepatitis c treatment when combined with viral GT and baseline plasma HCv-RNA load in the co-infected population. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, USA; abstract 945. Accessed at www.retroconference.org
43. Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum interferon-g-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011; 53:14-22.
44. Pineda JA, Caruz A, Di Lello F, et al. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIv/hepatitis C virus-coinfected patients. AIDS 2011; 25:1415-1420.
45. Hayes CN, Kobayashi M, Akuta N, et al. HCv substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011; 60:261-267.
46. Fattovich G, Covolo L, Bibert S, et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33:1162-1172.
47. Henning BJW, Heller S, Frodsham AJ, et al. Association of low-density lipoprotein receptor polymorphism and outcome of hepatitis C infection. Genes Immun 2002; 3:359-367. (Pubitemid 38967564)
48. Fischer DG, Tal N, Novick D, et al. An antiviral soluble form of the LDL receptor induced by interferon. Science 1993; 262:250-253 (Pubitemid 23344471)
49. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464:405-408.
50. Thompson AJ, Fellay J, Patel K, et al. variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139:120-129.
51. Rallón N, Morello J, Labarga P, et al. Impact of ITPA gene variants on the risk of anemia in HIv/HCv-coinfected patients treated for chronic hepatitis C. Clin Infect Dis 2011; (in press).
52. Guardiola J, Pacho C, Martín J, et al. ITPA polymorphism gene variants protect against RBv-induced anemia in HIv/HCv patients treated for chronic hepatitis C. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, USA; abstract 480. Accessed at www.retroconfer ence.org
53. Chu T, Kulkarni R, Gane E, et al. The effect of host IL28B genotype on early viral kinetics during interferon-free treatment in patients with chronic hepatitis C. J Hepatol 2011; 54 (Suppl 1):S521-S522.
54. van Heeswijk R, vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARv agents and the investigational HCv protease inhibitor TvR in healthy volunteers. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, USA; abstract 119. Accessed at www.retroconference.org